464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors. (September 2015) - Frampton, G.; Ali, S.; Rosenzweig, M.; Chmielecki, J.; Bauer, T.; Akimov, M.; Peters, M.; Bufill, J.; Lee, C.; Ou, I.; Salgia, R.; Yelensky, R.; et al.